AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16428539 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 1 mg/kg total body weight
Number of subjects: 45
Study 15571211 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 10 mg to 120 mg
Number of subjects: 154
Study 15571211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 11404656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (FIO2 = 0.75)
Number of subjects: 14
Study 11404656 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 14
Study 9146777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg daily
Number of subjects: 103
Study 9146777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 103
Study 8199904 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-concept assessment using the Tennessee Self-Concept Scale (TSCS)
Number of subjects: 471
Study 2451929 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 12
Study 2451929 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 12
Study 2451929 — intervention group
Group type: COMPARATOR
Intervention: Benzalkonium chloride
Number of subjects: 12
Study 2451929 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 12
Study 30194031 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-204 (50, 100, 200, 300, and 500mg twice daily)
Number of subjects: 23
Study 30194031 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-204 (200mg and above)
Number of subjects: 23
Study 30194031 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-204
Number of subjects: 23
Study 30652205 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct provision of an HIV self-test
Number of subjects: 960
Study 30652205 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of a coupon for facility collection of an HIV self-test
Number of subjects: 960
Study 30652205 — intervention group
Group type: COMPARATOR
Intervention: Referral to standard-of-care HIV testing services
Number of subjects: 960
Study 28181344 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-facilitated courses that encourage experiential learning
Number of subjects: 20
Study 26603802 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous haemofiltration (CVVH)
Number of subjects: 252
Study 26603802 — intervention group
Group type: COMPARATOR
Intervention: Intermittent haemodialysis (IHD)
Number of subjects: 252
Study 26603802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IHD and CVVH
Number of subjects: 252
Study 26603802 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH in patients with sepsis
Number of subjects: 252
Study 23188892 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-based treatment
Number of subjects: 324
Study 23188892 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose-lowering agents
Number of subjects: 324
Study 21602541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (HRP) with a polysomnographic cut-off of the apnoea-hypopnoea index (AHI)≥5
Number of subjects: 366
Study 21602541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (HRP) with a specific cut-off of AHI>10
Number of subjects: 366
Study 21602541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (HRP)
Number of subjects: 366
Study 21602541 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography
Number of subjects: 366
Study 18477373 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Exercise Self‐efficacy Project (SESEP) intervention
Number of subjects: 166
Study 18477373 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 166
Study 15389224 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine supplementation
Number of subjects: 200
Study 15389224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 11669482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (1450 ppm NaF)
Number of subjects: 8
Study 11669482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-free toothpaste
Number of subjects: 8
Study 9698952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.12% with fentanyl 2 micrograms/ml
Number of subjects: 100
Study 9698952 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.24% with fentanyl 4 micrograms/ml
Number of subjects: 100
Study 8016257 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 11
Study 8016257 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 11
Study 2472709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiated blood with lymphocytes
Number of subjects: 0
Study 2472709 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet irradiated blood without lymphocytes
Number of subjects: 0
Study 46511 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated group
Number of subjects: 63
Study 46511 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 46511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 30951597 — intervention group
Group type: COMPARATOR
Intervention: 0% CLA
Number of subjects: 360
Study 30951597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% CLA
Number of subjects: 360
Study 30951597 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CLA
Number of subjects: 360
Study 30951597 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% CLA
Number of subjects: 360
Study 28661759 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) followed by docetaxel (100 mg/m2; EC-D)
Number of subjects: 2012
Study 28661759 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2) and cyclophosphamide (600 mg/m2; DC)
Number of subjects: 2012
Study 25937436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin 1000-1200 mg daily for 24 weeks
Number of subjects: 103
Study 25937436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin 1000-1200 mg daily for 12 weeks
Number of subjects: 103
Study 25937436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin for 12 weeks in patients with cirrhosis
Number of subjects: 103
Study 25937436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin for 24 weeks in patients with cirrhosis
Number of subjects: 103
Study 25937436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin for 12 weeks in patients without cirrhosis
Number of subjects: 103
Study 25937436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin for 24 weeks in patients without cirrhosis
Number of subjects: 103
Study 23998146 — intervention group
Group type: EXPERIMENTAL
Intervention: New dentures (Kennedy Class I or II RPDs)
Number of subjects: 72
Study 23998146 — intervention group
Group type: EXPERIMENTAL
Intervention: New dentures (Kennedy Class III or IV RPDs)
Number of subjects: 72
Study 23998146 — intervention group
Group type: EXPERIMENTAL
Intervention: New complete dentures
Number of subjects: 72
Study 23998146 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 72
Study 21454449 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (1494 men)
Number of subjects: 9026
Study 21454449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be the remaining men)
Number of subjects: 9026
Study 21454449 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 9026
Study 21454449 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (after adjustment for age)
Number of subjects: 9026
Study 19803235 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with catgut implantation at acupoints
Number of subjects: 65
Study 19803235 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture only (control group)
Number of subjects: 65
Study 16775230 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous interferon beta‐1a at 22 mug, three times weekly
Number of subjects: 24
Study 16775230 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous interferon beta‐1a
Number of subjects: 24
Study 15280789 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 28
Study 15280789 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 28
Study 11446955 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative strategies to optimize results in older patients
Number of subjects: 0
Study 11446955 — intervention group
Group type: COMPARATOR
Intervention: Clinical trials
Number of subjects: 0
Study 11446955 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 9252074 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU interferon alpha-2b t.i.w. for 21 months
Number of subjects: 171
Study 9252074 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MU interferon alpha-2b t.i.w. for 21 months
Number of subjects: 171
Study 9252074 — intervention group
Group type: COMPARATOR
Intervention: 3 MU interferon alpha-2b
Number of subjects: 171
Study 9252074 — intervention group
Group type: COMPARATOR
Intervention: 6 MU interferon alpha-2b
Number of subjects: 171
Study 9252074 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline viremia
Number of subjects: 171
Study 9252074 — intervention group
Group type: COMPARATOR
Intervention: Genotype 1b
Number of subjects: 171
Study 12959273 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 0
Study 12959273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (60 mg)
Number of subjects: 0
Study 3103580 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate therapy
Number of subjects: 104
Study 3103580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 29447788 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat for 6 weeks
Number of subjects: 30
Study 29447788 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 30
Study 27288382 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated identification and notification of clinician of high-risk patients by APPROVE or by invasive MV and checklist of evidence-based practices in ARF (Prevention of Organ Failure Checklist‐PROOFCheck)
Number of subjects: 0
Study 25483483 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study 22545878 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative duplex ultrasonography (DUS)
Number of subjects: 100
Study 22545878 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-modality early postoperative follow-up protocol (intraoperative angiogram, DUS, and abdominal radiograph)
Number of subjects: 100
Study 22545878 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-modality early postoperative follow-up protocol
Number of subjects: 100
Study 22545878 — intervention group
Group type: COMPARATOR
Intervention: Initial postoperative computed tomographic angiography (CTA)
Number of subjects: 100
Study 19945354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient sham TENS
Number of subjects: 69
Study 19945354 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 69
Study 19945354 — intervention group
Group type: COMPARATOR
Intervention: Inactive sham
Number of subjects: 69
Study 19945354 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher active TENS amplitudes (> or =17 mAs)
Number of subjects: 69
Study 19945354 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower active TENS amplitudes (<17 mAs)
Number of subjects: 69
Study 18306163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Er:YAG laser ablation and ALA methyl ester PDT (method C)
Number of subjects: 286
Study 18306163 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) only (method A)
Number of subjects: 286
Study 18306163 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser ablation only (method B)
Number of subjects: 286
Study 15708302 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14
Study 15708302 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 14
Study 11994041 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 12 weeks
Number of subjects: 48
Study 11994041 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 150 mg once weekly for 12 weeks
Number of subjects: 48
Study 11994041 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 150 mg once weekly for 24 weeks
Number of subjects: 48
Study 10460185 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ET plus active US
Number of subjects: 180
Study 10460185 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ET plus dummy US
Number of subjects: 180
Study 10460185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dummy ET plus active US
Number of subjects: 180
Study 10460185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dummy ET plus dummy US
Number of subjects: 180
Study 10460185 — intervention group
Group type: COMPARATOR
Intervention: No adjuvants
Number of subjects: 180
Study 8546284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 45
Study 8546284 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 45
Study 8546284 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (propofol and alfentanil)
Number of subjects: 45
Study 2121846 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg orally every 6 months)
Number of subjects: 6
Study 2121846 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (initial full dose of 40 mg/kg followed by 20 mg/kg every 3 months)
Number of subjects: 6
Study 2121846 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (initial loading dose followed by 20 mg/kg at monthly intervals)
Number of subjects: 6
Study 2121846 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (20 mg/kg orally monthly)
Number of subjects: 6
Study 2121846 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (20 mg/kg orally every 3 months)
Number of subjects: 6
Study 2121846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin B complex tablets at 3-month intervals)
Number of subjects: 6
Study 2121846 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg orally every 6 months for urinary hematobiasis)
Number of subjects: 6
Study 2121846 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (20 mg/kg orally monthly for urinary hematobiasis)
Number of subjects: 6
Study 2121846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two vitamin B-complex tablets monthly for urinary hematobiasis)
Number of subjects: 6
Study 342691 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (CP 16171)
Number of subjects: 0
Study 31190359 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (1,000 mg omega-3 fatty acids, twice a day for 12 weeks)
Number of subjects: 90
Study 31190359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1,000 mg omega-3 fatty acids, twice a day for 12 weeks)
Number of subjects: 90
Study 27988143 — intervention group
Group type: EXPERIMENTAL
Intervention: EUC plus HAP
Number of subjects: 495
Study 27988143 — intervention group
Group type: COMPARATOR
Intervention: EUC alone
Number of subjects: 495
Study 25597870 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP trajectory post-discharge
Number of subjects: 1351
Study 24304731 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (60 min/5 days/week at 60‐85% of heart rate reserve) for 12 weeks
Number of subjects: 16
Study 24304731 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1 g/day) for 12 weeks
Number of subjects: 16
Study 21729238 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine 0.3 mg per day
Number of subjects: 28
Study 21729238 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine 0.45 or 0.6 mg per day
Number of subjects: 28
Study 21729238 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 28
Study 19250299 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulse Nd:YAG laser
Number of subjects: 19
Study 19250299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 585/1,064-nm laser
Number of subjects: 19
Study 19250299 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic evaluations
Number of subjects: 19
Study 19250299 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction scores
Number of subjects: 19
Study 16409456 — intervention group
Group type: COMPARATOR
Intervention: 9000 aXa-units of unfractionated heparin (UFH)
Number of subjects: 12
Study 16409456 — intervention group
Group type: EXPERIMENTAL
Intervention: Three heparins with narrow MW distribution around 10.5, 6.0 and 4.5 kD (LMWHs)
Number of subjects: 12
Study 16409456 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 12
Study 16409456 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWHs
Number of subjects: 12
Study 15354517 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (Group B)
Number of subjects: 48
Study 15354517 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group A)
Number of subjects: 48
Study 15354517 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusis (Group C)
Number of subjects: 48
Study 15354517 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Group D)
Number of subjects: 48
Study 10954344 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cocaine administration
Number of subjects: 0
Study 10954344 — intervention group
Group type: COMPARATOR
Intervention: Oral cocaine administration
Number of subjects: 0
Study 10954344 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cocaine administration
Number of subjects: 0
Study 10618527 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (aP)
Number of subjects: 749
Study 10618527 — intervention group
Group type: COMPARATOR
Intervention: Tetanus-diphtheria vaccine (Td)
Number of subjects: 749
Study 10618527 — intervention group
Group type: COMPARATOR
Intervention: Combined diphtheria-tetanus-acellular pertussis vaccine (TdaP)
Number of subjects: 749
Study 8859258 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (2 mg/kg) in patients with HPS
Number of subjects: 24
Study 8859258 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (2 mg/kg) in healthy control subjects
Number of subjects: 24
Study 8859258 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide therapy in patients with HPS
Number of subjects: 24
Study 8859258 — intervention group
Group type: COMPARATOR
Intervention: Furosemide therapy in healthy children
Number of subjects: 24
Study 1514335 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 29
Study 1514335 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture treatment (Group A) + No-treatment control (Group B)
Number of subjects: 29
Study 1514335 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Group A)
Number of subjects: 29
Study 6391771 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose verapamil (480 mg/day)
Number of subjects: 46
Study 6391771 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg/day)
Number of subjects: 46
Study 29361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling black tea aroma (Darjeeling and Assam)
Number of subjects: 0
Study 29361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling Darjeeling tea aroma
Number of subjects: 0
Study 29361988 — intervention group
Group type: COMPARATOR
Intervention: Water exposure control
Number of subjects: 0
Study 26806757 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic surgery
Number of subjects: 45
Study 26806757 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic surgery
Number of subjects: 45
Study 24446242 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin > median
Number of subjects: 159
Study 24446242 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP > 25th percentile
Number of subjects: 159
Study 24446242 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation in both serum ferritin and CRP
Number of subjects: 159
Study 24446242 — intervention group
Group type: COMPARATOR
Intervention: No elevation in both biomarkers
Number of subjects: 159
Study 22133656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intravenously
Number of subjects: 76
Study 22133656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 19945093 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction during contingency reversals (Experiment 1)
Number of subjects: 0
Study 19945093 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction during extinction (Experiment 2)
Number of subjects: 0
Study 17400981 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast injection (over four seconds, Group F) of 0.75% hyperbaric bupivacaine 12 mg plus morphine 200 microg
Number of subjects: 90
Study 17400981 — intervention group
Group type: COMPARATOR
Intervention: Slow injection (over 40 seconds, Group S) of 0.75% hyperbaric bupivacaine 12 mg plus morphine 200 microg
Number of subjects: 90
Study 15567812 — intervention group
Group type: COMPARATOR
Intervention: IG‐IH nerve block (Group I)
Number of subjects: 98
Study 15567812 — intervention group
Group type: EXPERIMENTAL
Intervention: IG‐IH and genitofemoral nerve blocks (Group II)
Number of subjects: 98
Study 12175715 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 40 mg vaginally
Number of subjects: 107
Study 12175715 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 50 microg vaginally
Number of subjects: 107
Study 9789972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle blood pressure measurement (ABP)
Number of subjects: 182
Study 9789972 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pulse plethysmography (inclination time - IT)
Number of subjects: 182